Results 131 to 140 of about 37,026 (217)

Nicotine oxidation by genetic variants of CYP2B6 and in human brain microsomes [PDF]

, 2019
Bloom, Adam Joseph, Kharasch, Evan D, Wang, Pan-Fen   +2 more
core   +2 more sources

Vareniclina. Un paso más en la lucha contra el tabaquismo [PDF]

, 2007
Recientemente la Food and Drugs Administration ha aprobado Vareniclina, fármaco para la deshabituación tabáquica que presenta un novedoso mecanismo de acción, agonismo parcial de receptores nicotínicos de acetilcolina a4ß2.Hemos revisado la farmacología,
Donat, Lucas, Ferrando Piqueres, Raúl, Martínez, Beatriz, Milara Payá, Javier, Pérez Prior, Noemí, Soler Company, Enrique   +5 more
core  

Physical and Behavioral Health Diagnoses and Comorbidities Associated With Transition From Military Health System to Veterans Health Care Among Post‐9/11 Veterans

Health Services Research, Volume 61, Issue 2, April 2026.
ABSTRACT Objective To identify factors associated with transitioning from Military Health System (MHS) to Veterans Health Administration (VHA) care in post‐9/11 veterans. Study Setting and Design Retrospective cohort study from the Long‐Term Impact of Military‐Relevant Brain Injury Consortium Phenotype Study. Data Sources and Analytic Sample Population‐
Nikki R. Wooten, Megan E. Amaun, Madeleine Myers, Prince N. O. Addo, Jeffrey Bowers, Felicia R. Carey, Rudolph P. Rull, Edward J. Boyko, Nathaniel Bell, Ana DeFede‐Lopéz, Mary Jo V. Pugh   +10 more
wiley   +1 more source

Naltrexone HCI/bupropion HCI for chronic weight management in obese adults: patient selection and perspectives

Patient Preference and Adherence, 2016
Cenk Tek Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA Abstract: Naltrexone, an opiate antagonist, and bupropion, a noradrenergic/dopaminergic antidepressant, have many effects on the reward systems of the brain.
Tek C
doaj  

Patients' Perspectives on Antidepressant Discontinuation and the Pharmacists' Role

Basic &Clinical Pharmacology &Toxicology, Volume 138, Issue 4, April 2026.
ABSTRACT Antidepressant (AD) discontinuation care asks for tailored support and alignment with patients' expectations, needs and wishes. However, studies on patients' experiences and perspectives regarding the contribution of the pharmacist to AD discontinuation care are limited.
Samah Bouarfa, Wilma Göttgens, Suzanne A. Ligthart, Otto R. Maarsingh, Marcel J. Kooij, Pierre M. Bet, Jacqueline G. Hugtenburg   +6 more
wiley   +1 more source

Rationale and design of a parallel randomised trial of a plant‐based intensive lifestyle intervention for diabetes remission: The REmission of diabetes using a PlAnt‐based weight loss InteRvention (REPAIR) trial

Diabetes, Obesity and Metabolism, Volume 28, Issue 4, Page 2627-2641, April 2026.
Abstract Aims As type 2 diabetes (T2D) continues to rise globally and remains a major driver of cardiovascular disease, its remission has emerged as a therapeutic target. Current evidence supports bariatric surgery and low‐calorie diets with meal replacements.
Brighid McKay, Dayana El Chaar, Melanie Paquette, Michael Vallis, Diana Sherifali, Paul Oh, Susan Marzolini, Kaberi Dasgupta, Gillian Booth, Mike Lean, Hertzel C. Gerstein, Jordi Salas‐Salvadó, Jacqueline L. Beaudry, Christopher P. F. Marinangeli, Russell J. de Souza, Lawrence A. Leiter, Cyril W. C. Kendall, David J. A. Jenkins, John L. Sievenpiper, Laura Chiavaroli   +19 more
wiley   +1 more source

Understanding Impact of Anti‐Obesity Medications on Skeletal Muscle Mass Change Is Confounded by Measurement Methods

Obesity Reviews, Volume 27, Issue 4, April 2026.
ABSTRACT Anti‐obesity medications promote greater degrees of weight loss than lifestyle interventions alone. There is an important need to understand whether loss of skeletal muscle during pharmacologically induced weight loss is clinically significant due to its essential role in health and disease.
Arden McMath, Dympna Gallagher
wiley   +1 more source

Pharmacokinetics, pharmacodynamics and safety of vutiglabridin after multiple oral administrations in healthy female and obese subjects

British Journal of Clinical Pharmacology, Volume 92, Issue 3, Page 860-868, March 2026.
Aims Vutiglabridin (HSG4112) is a novel drug under clinical development for antiobesity treatment. This study aimed to evaluate the pharmacokinetics (PKs) and safety of vutiglabridin after multiple oral administrations in healthy Korean female and obese subjects and explore short‐term pharmacodynamic (PD) responses.
Sooyoun Lee, Hyun Chul Kim, Young Ran Yoon, In‐Jin Jang, Sang‐Ku Yoo, Kyung‐Sang Yu   +5 more
wiley   +1 more source

Risk of gastrointestinal bleeding by specific SSRIs and SNRIs: A systematic review and meta‐analysis

British Journal of Clinical Pharmacology, Volume 92, Issue 3, Page 793-808, March 2026.
Aim The purpose of this study is to estimate the risk of gastrointestinal bleeding (GIB) by selective serotonin reuptake inhibitors (SSRIs) and serotonin–norepinephrine reuptake inhibitors (SNRIs) individual agents. Methods A systematic review was conducted for each unique antidepressant (i.e.
Ainhoa Gomez‐Lumbreras, Abdelrahman G. Tawfik, Guilherme Del Fiol, Kensaku Kawamoto, Thomas Reese, Katy Trinkley, Aubrey Jones, James Mitchell, Daniel C. Malone   +8 more
wiley   +1 more source

Managing Antidepressant‐Induced Hyperhidrosis With Vitamin E: An Over‐the‐Counter Supplement–Based Approach

Clinical Case Reports, Volume 14, Issue 3, March 2026.
ABSTRACT Excessive sweating is a common side effect of antidepressants, affecting approximately 22% of patients. Antidepressant‐induced excessive sweating (ADIES) can significantly impair quality of life and medication adherence. This case report explores the use of Vitamin E as a novel adjunct treatment for ADIES.
Saad Nazir, Mahnoor Azmat, Neha Prathivadi, Divyaraj Bavishi, Yasin Ibrahim   +4 more
wiley   +1 more source